Insmed Q3 2021 Earnings Report
Key Takeaways
Insmed reported a revenue of $46.8 million for the third quarter of 2021, compared to $43.6 million for the third quarter of 2020. The company's GAAP net loss was $112.7 million, or $0.96 per share, compared to a GAAP net loss of $63.7 million, or $0.63 per share, for the third quarter of 2020. The company had cash and cash equivalents of $846.6 million as of September 30, 2021.
Total revenue for Q3 2021 was $46.8 million, compared to $43.6 million for Q3 2020.
Insmed launched ARIKAYCE in Japan in July 2021 and is seeing positive early trends.
GAAP net loss for Q3 2021 was $112.7 million, or $0.96 per share, compared to a GAAP net loss of $63.7 million, or $0.63 per share, for Q3 2020.
Cash and cash equivalents totaled $846.6 million as of September 30, 2021.
Insmed
Insmed
Forward Guidance
Insmed plans to continue to invest in the U.S. commercialization of ARIKAYCE, launch activities for ARIKAYCE in initial European countries and in Japan, and clinical trial activities.
Positive Outlook
- U.S. commercialization of ARIKAYCE
- Launch activities for ARIKAYCE in initial European countries and in Japan
- Advancement of the frontline clinical trial program for ARIKAYCE (ARISE and ENCORE)
- Advancement of the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis
- Advancement of clinical development of TPIP